Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCFR1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,688
Award facts
- Contract value 100% obligated
- $23,688.35 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $23,688.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for XOLAIR 150 mg/mL syringes. The contract, issued on January 29, 2026, with an ultimate completion date of February 20, 2026, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive acquisition strategy established to support the Department of Defense's pharmaceutical supply needs globally.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability as a critical supplier within the military healthcare supply chain, with its product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The underlying PPV-G GEN V contract, awarded in November 2025, carries a ceiling value of $499.999 billion and extends through December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting the $30.3 billion acquisition strategy. The company's established performance on numerous delivery orders across diverse therapeutic categories reflects its capacity to fulfill the specialized pharmaceutical requirements of Department of Defense healthcare operations worldwide.
Quick answers
Who was awarded contract SPE2DR26FCFR1?
SPE2DR26FCFR1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FCFR1 worth?
The government has obligated $23,688 on SPE2DR26FCFR1.
Is contract SPE2DR26FCFR1 an order under another contract?
Yes. SPE2DR26FCFR1 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFR1 competed?
The extent of competition for SPE2DR26FCFR1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award